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BMP-2 and BMP-2/7 Heterodimers Conjugated
to a Fibrin/Hyaluronic Acid Hydrogel in a Large Animal
Model of Mild Intervertebral Disc Degeneration
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Avner Yayon,4 Franz E. Weber,3 and Marco N. Helder1,2,*
Abstract
Intervertebral disc (IVD) degeneration is etiologically associated with low back pain and is currently only treated
in severe cases with spinal fusion. Regenerative medicine attempts to restore degenerated tissue by means of
cells, hydrogels, and/or growth factors and can therefore be used to slow, halt, or reverse the degeneration
of the IVD in a minimally invasive manner. Previously, the growth factors bone morphogenetic proteins 2 and
7 (BMP-2, -7) were shown to enhance disc regeneration, in vitro and in vivo. Since BMPs have only a short
in vivo half-life, and to prevent heterotopic ossiﬁcation, we evaluated the use of a slow release system for BMP-
2 homodimers and BMP-2/7 heterodimers for IVD regeneration. BMP growth factors were conjugated to a ﬁ-
brin/hyaluronic acid (FB/HA) hydrogel and intradiscally injected in a goat model of mild IVD degeneration to
study safety and efﬁcacy. Mild degeneration was induced in ﬁve lumbar discs of seven adult Dutch milk goats,
by injections with the enzyme chondroitinase ABC. After 12 weeks, discs were treated with either FB/HA-hydrogel
only or supplemented with 1 or 5lg/mL of BMP-2 or BMP-2/7. BMPs were linked to the FB/HA hydrogels using a
transglutaminase moiety, to be released through an incorporated plasmin cleavage site. After another 12 weeks,
goats were sacriﬁced and discs were assessed using radiography, MRI T2* mapping, and biochemical and histolog-
ical analyses. All animals maintained weight throughout the study and no heterotopic bone formation or other
adverse effects were noted during follow-up. Radiographs showed signiﬁcant disc height loss upon induction
of mild degeneration. MRI T2* mapping showed strong and signiﬁcant correlations with biochemistry and histol-
ogy as shown before. Surprisingly, no differences could be demonstrated in any parameter between intervention
groups. To our knowledge, this is the ﬁrst large animal study evaluating BMPs conjugated to an FB/HA-hydrogel for
the treatment of mild IVD degeneration. The conjugated BMP-2 and BMP-2/7 appeared safe, but no disc regener-
ation was observed. Possible explanations include too low dosages, short follow-up time, and/or insufﬁcient release
of the conjugated BMPs. These aspects should be addressed in future studies.
Key words: bone morphogenetic protein; ﬁbrin/hyaluronic acid hydrogel; intervertebral disc; large animal
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Introduction
Low back pain has been the worldwide leading cause of
years lived with disability for several decades according
to the Global Burden of Disease Study 2010.1 Interver-
tebral disc (IVD) degeneration has–among other con-
tributing factors–been established as an important
etiological feature of low back pain.2 Standard medical
care for severe painful disc degeneration currently
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consists of conservative therapy for pain reduction,
physiotherapy, and invasive surgical procedures like spi-
nal fusion.3 However, conventional clinical practice has
not yet provided an elegant, minimally invasive treat-
ment modality for disc degeneration at an early stage.
Regenerative medicine aims to address disc degenera-
tion at an early stage, where (stem) cells, extracellular
matrix-supporting hydrogels, and/or growth factors
are promising candidates to slow, halt, or reverse the
degenerative process.4–6 In addition, these promising
solutions can be executed using minimally invasive pro-
cedures and will therefore prevent high surgical costs
while maintaining or improving quality of life.
Bone morphogenetic proteins (BMPs), a widely used
group of growth factors, are anabolic, multipotent pro-
teins that are involved in skeletal development and re-
pair.7,8 Besides their role in osteogenesis, BMPs also
play an important role in chondrogenesis and the
maintenance of the extracellular matrix of articular
and IVD cartilage.9 Several research groups have inves-
tigated the regenerative potential of BMPs for IVD ap-
plications, both in vivo and in vitro. BMP-2 has been
demonstrated to increase extracellular matrix expres-
sion and synthesis in rat, bovine, and human IVD
cells, without expression of an osteogenic pheno-
type.10–14 Similarly, BMP-7 has been shown to promote
extracellular matrix metabolism in rat and rabbit IVD
cells.15,16 Also, a beneﬁcial effect of BMP-7 on human
nucleus pulposus (NP) and annulus ﬁbrosis (AF) cells
was identiﬁed, as demonstrated by an increased cell
proliferation and proteoglycan synthesis.17 However,
although proteoglycan production increased over
time, this effect was slower than observed in rabbit
and bovine NP and AF cells receiving a similar dose
of BMP-7.15,18 In vivo, intradiscal injection of adenovi-
ral vectors carrying the BMP-2 gene slowed down IVD
degeneration in a rabbit annular puncture model.7 In
addition, injection of BMP-7 increased disc height
and proteoglycan content in both an annular puncture
and enzymatically degenerated disc rabbit model.5,19
BMP-2 has also been applied for lumbar interbody fu-
sion to induce bone formation, but this has led to severe
adverse effects, including heterotopic ossiﬁcation, retro-
grade ejaculation, and possible increased risk ofmalignan-
cy.20–22 Heterotopic bone formation following lumbar
spinal fusion supplemented with BMP-2 or BMP-7 is
described in several studies with varying incidence
rates.23–26 A systematic review in 2010 reported a mean
rate of 8% (range 0–75%) for heterotopic bone formation
associated with BMP use in lumbar spine surgery.22
In this study, it should be mentioned that the studies in
which these complications were reported used high
doses of BMPs (3.5–12mg BMP per treated level).
To enhance IVD regeneration but avoid heterotopic
ossiﬁcation outside of the IVD, slow release drug delivery
systems may be applied. Moreover, the delayed regener-
ative inductive response of human IVD cells to BMP-7
and the short in vivo circulation times of BMPs imply
an advantageous effect of a prolonged exposure to
BMPs.27 One suitable slow release system utilizes cova-
lent incorporation of BMPs using transglutaminase
(TG) crosslinking into a hydrogel of ﬁbrin and hyalur-
onic acid (FB/HA). This FB/HA hydrogel has previously
been shown to support NP-cell function and restores
disc height and compressive stiffness ex vivo.28 In vitro
experiments demonstrated that covalently bound
BMPs can be retained in ﬁbrin hydrogels until released
by cells through an included plasmin-cleavable site.29,30
Treatment of a critical-size cranial defect in rats with
this BMP-2 coupled to a ﬁbrin gel induced 76% more
bone formation compared to the wild-type recombinant
human BMP-2 (rhBMP-2).29 A recent study reproduced
these ﬁndings and also demonstrated that the BMP-2/7
heterodimer conjugated to a ﬁbrin hydrogel was more
efﬁcacious compared with the commonly used BMP-2
homodimer in a similar rat calvarial defect.30
This study evaluated the safety and efﬁcacy of a
novel slow release BMP technology for IVD regenera-
tion in a previously validated goat IVD degeneration
model.31 After induction of mild IVD degeneration
with chondroitinase ABC (CABC), intradiscal injec-
tions of 1 or 5 lg/mL of either BMP-2 or BMP-2/7, co-
valently conjugated to the FB/HA hydrogel, were
performed. After a follow-up time of 12 weeks, safety
and efﬁcacy were assessed using multiple outcome
parameters (radiography, MRI T2* mapping, and bio-
chemical and histological analyses). Besides a dose–
response effect, this setup also allowed a comparison
in effectiveness between the BMP-2 homodimer and
the BMP-2/7 heterodimer for IVD regeneration.
Materials and Methods
Animals and surgical procedure
Both the Scientiﬁc Board and the Animal Ethics Com-
mittee of the VU University Medical Centre approved
the research protocol. Seven skeletally mature female
Dutch milk goats (average age: 3.8– 1.5 years) with an
average weight of 74– 11 kg were used for this study.
All goats underwent two surgeries: in the ﬁrst procedure,
lumbar IVDs (L1L2–L5L6) of each goat were injected
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with 0.25U/mLCABC dissolved in PBS using a 29G nee-
dle, whereas another disc (T13L1) was left as a healthy
control. CABC cleaves proteoglycans and thereby mim-
ics disc degeneration, as validated previously in our
group.31 During the second procedure, 12 weeks
later, IVDs were injected with the FB/HA hydrogels
supplemented with either BMP-2 or BMP-2/7 in two
concentrations or with hydrogel only (vehicle con-
trol), prepared as described below. After the second
surgery, goats were monitored for 12 weeks at which
point they were sacriﬁced, and lumbar spines (T13–
L6) where harvested for further analysis.
Production of BMPs and crosslinking
to a hydrogel carrier
In the present study, a ﬁbrinogen/hyaluronic acid (FB/
HA) conjugate was used as a carrier for the BMP-2 and
the BMP-2/7 dimers. rhBMP-2 containing extra-amino
acids for TG crosslinking and plasmin cleavage sites
(pl) at the N terminus was produced as described pre-
viously.29,32 Brieﬂy, the DNA encoding for the TG and
pl amino acids were cloned into a plasmid containing
the genetic sequence for rhBMP-2 (pET23aBMP2 vec-
tor) and transfected into the E. coli bacteria. TG-pl-
BMP-2monomers were produced with standard protein
expression procedures. Obtained monomers were puri-
ﬁed through afﬁnity and size exclusion chromatography,
subsequently refolded, and in a ﬁnal puriﬁcation step,
dimers were separated from monomers and unfolded
growth factors (Fig. 1). For the production of the TG-
pl-BMP-2/BMP-7 heterodimer, rhBMP-7 was added
during refolding and dimerization (Fig 1, step 4). Final
concentrations of the produced TG-pl-BMP-2 proteins
and TG-pl-BMP-2/BMP-7 were determined. The engi-
neered fused growth factors are henceforth mentioned
as TG-BMP-2 and TG-BMP-2/7. FB/HA conjugates
were synthesized by the reaction of a buffered ﬁbrinogen
solution with a HA-active ester solution using HAwith a
molecular weight of 235 kDa, and the ratio FB/HA was
17:1(ProCore Bio Med Ltd.).28 TG-BMPs were mixed in
a thrombin solution (5.2U/mL). Just before injection,
FB/HA conjugates and the TG-BMP-containing throm-
bin solution were mixed and injected into the IVD be-
fore polymerization. For each TG-BMP, two different
concentrations were used, with a ﬁnal concentration of
TG-BMP in the hydrogels of 1 or 5lg/mL.
Radiological analysis
Before both surgeries and autopsy, standardized lateral
lumbar radiographs were obtained. For each IVD, a
disc height index (DHI) was calculated as previously
described.33 In short, the height of the IVD and adja-
cent caudal vertebral body were measured by averaging
three measurements. DHI was then calculated by divid-
ing the average IVD height by the vertebral body
height, thus correcting for interanimal size differences.
Magnetic resonance imaging
MRI scans were acquired from all lumbar spines
within 2–3 h after autopsy using a 1.5T MR scanner
(Magnetom Symphony, Syngo MR VA30; Siemens
Healthcare). Sagittal scans were performed using a
T2-weighted turbo spin echo (TSE) sequence, followed
by a multiecho gradient echo sequence for T2* map-
ping (echo times of 5.7, 10.9, 16.05, 21.2, and
26.4msec) as recently described and validated in our
group.34 T2* relaxation times were calculated by ﬁtting
the signal intensities of the ﬁve echo times, for ﬁve re-
gions of interest (ROIs) covering the IVD from anterior
to posterior. The ROIs were drawn in a similar manner
for all discs, according to a proportional division; ROIs
1 and 3 covered 27.5% of total disc diameter, whereas
ROIs 2, 4, and 5 each covered 15%. This way ROIs 1,
3, and 5 represent the anterior AF, NP, and posterior
AF, respectively. ROIs 2 and 4 represent the transition
zones between NP and AF and were not used for fur-
ther analysis. By copying the ROIs drawn in the ﬁrst se-
ries into the subsequent series, the ROI size and
position were kept equal for all echo times. T2* relax-
ation times were calculated by ﬁtting the echo time in-
tensities using a linear-log least-squares method using
Microsoft Excel (Microsoft Ofﬁce 2010).
Histological evaluation
After obtaining MR images, all lumbar IVDs (T13L1–
L5L6), including endplates were dissected from the
spine and a 4mm paramidsagittal slice was obtained
using a band saw (Exakt, Norderstedt, Germany). Sec-
tions were ﬁxed in 4% formaldehyde, decalciﬁed in
Kristensen’s ﬂuid, cut into 3 lm thin sections using a
microtome, and stained with hematoxylin and eosin
and Alcian Blue-Periodic Acid Schiff. Sections were an-
alyzed using light microscopy, and degeneration grad-
ing was scored by two blinded independent researchers
on different parameters optimized for goat IVD degen-
eration, as described and validated previously.33 Differ-
ences in scoring between the observers were resolved
by consensus, resulting in a ﬁnal histological score
ranging between 0 (healthy) and 6 (severely degener-
ated disc).
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Biochemical analysis
Tissue samples for biochemical analysis were obtained
from an adjacent slice to the histological section; ante-
rior AF, NP, and posterior AF were harvested, that is,
from MRI ROIs 1, 3, and 5, respectively. Samples were
freeze-dried (speedvac) and subsequently digested in
1.5mL papain-digestion buffer containing 0.1M sodium
acetate, 0.01M L-cysteine, and 0.01M EDTA, after
which pH was titrated to 6.6 using 1M NaOH and ﬁ-
nally 0.33% (w/v) papain was added to the solution
(all Merck Millipore). Samples were digested overnight
in a continuously shaking water bath at 65 C. Papain
digestion solutions were diluted and glycosaminoglycan
(GAG) content was analyzed using a DMMB assay (Bio-
color Ltd.) according to the manufacturer’s protocol.
The collagen content, expressed as the total amount of
hydroxyproline (HYP), was quantiﬁed using a DMBA
hydroxyproline assay, as described by Paul et al.35 Meas-
ured amounts of GAG and HYP content were expressed
in micrograms per milligram tissue dry weight.
FIG. 1. (a) Schematic overview of the engineered TG-BMP-2 homodimer, containing two transglutaminase
(TG) crosslinking sites and two plasmin (pl) cleavage sites. (b) Schematic overview of the engineered TG-BMP-
2/BMP-7 heterodimer. (c) Production of the TG-BMP2 homodimer and TG-BMP2/7 heterodimer. Starting with
the engineering of a BMP-2 plasmid vector containing two extra-amino acid sequences; TG for crosslinking the
BMP-2 onto the ﬁbrin and a plasmin site to allow enzymatically cleaving off the growth factor from the ﬁbrin.
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Statistical analysis
The results of the DHI were analyzed using a Wilcoxon
signed-rank test. Outcome parameters were compared
and analyzed by a one-way analysis of variance
(ANOVA) using a Tukey post hoc test for parametric
data and the Kruskal–Wallis test for nonparametric
data. Linear regression analyses between MRI T2*
relaxation times and biochemical content and histological
grades were performed. Correlations between variables
were analyzed for statistical signiﬁcance using Spear-
man’s rho (q) coefﬁcients. Correlations were considered
strong for q> 0.7, moderate for 0.5<q£ 0.7, weak for
q£ 0.5, and signiﬁcant for p< 0.05. All data were also an-
alyzed using linear mixed models, where goat was in-
cluded as a random factor. Bonferroni’s post hoc testing
was used to compare the means of different outcome pa-
rameters between experimental groups. Differences were
considered statistically signiﬁcant for p< 0.05. Statistics
was performed using SPSS version 20.0 (SPSS Institute)
or GraphPad Prism 6 (GraphPad Software, Inc.).
Results
After both surgeries, all goats recovered well and showed
normal ambulatory activities on the ﬁrst postoperative
day and body weight was maintained during follow-
up. We found no signiﬁcant differences in injected vol-
umes of CABC ( p= 0.33) between all experimental
groups. The treated IVDs received an equal volume of
injected vehicle or TG-BMP-hydrogel combinations
( p= 0.59) (Table 1). This indicates a comparable
CABC induction of mild degeneration and subsequent
TG-BMP treatment for all intervention groups.
Radiological analysis
Injection of CABC into the IVDs resulted in a signiﬁ-
cant decrease ( p = 0.002) of 6% in DHI compared to
initial DHI, representing one of the initial symptoms
of IVD degeneration. Radiographs, taken before the
second surgery, revealed a fractured endplate in one
IVD; this disc was excluded from further analysis on
the effect of the BMPs. Calciﬁcation of the NP was ob-
served in one other IVD, prior the ﬁrst surgery, as
shown on radiographs and MRI scans, this disc was
not used in the T2* relaxation time analysis for the dif-
ferent intervention groups. Radiographs and MRI
scans did not reveal any osteophyte formation or
other endplate irregularities.
Effect of TG-BMPs
To assess regeneration following the injection of BMPs
into the NP, many different parameters were analyzed.
First, MRI T2* maps showed a signiﬁcant difference
in the relaxation times calculated for the NP (51.7–
14.5msec) compared to anterior (20.0– 1.9msec) and
posterior annulus ﬁbrosus (18.1– 4.3msec) ( p< 0.0001).
We did not ﬁnd a regenerative response, based on the
MRI T2* relaxation times, initiated by the administration
of the TG-BMP-2 and TG-BMP-2/7 conjugated to a
hydrogel carrier ( p= 0.67). As early regeneration will
start in the NP, the results showed focus mainly on the
NP (Table 2). In line with the results found for the T2*
relaxation times, we did not ﬁnd any signiﬁcant differ-
ences in the biochemical composition of the NP, as mea-
sured by the amount of glycosaminoglycans (GAG) and
collagen content (HYP) between all different treatments
(GAG, p= 0.15 and HYP, p= 0.32).
Histological grading of the IVDs revealed severe de-
generation in three IVDs. One of these discs concerns
the IVD with a fractured endplate, which was observed
before the second surgery and can therefore not be at-
tributed to the injection of the TG-BMPs. Another se-
verely degenerated disc is part of the negative control
group and thus did not receive any TG-BMPs. Apart
from one IVD, no severe degeneration in the TG-
BMP groups was observed, suggesting that the doses
TG-BMPs used in this study can be safely administered
to the IVD. Mean histological score for all discs was
2.19 (–1.3) and no signiﬁcant differences were ob-
served comparing all interventions ( p= 0.74).
We found large interanimal differences in the differ-
ent analyzed parameters, and further evaluation using
ANOVA revealed a signiﬁcant effect of the factor
goat for the HYP content, MRI T2* relaxation times,
and histological grading. From earlier studies we
know these variations can nullify the effect of the actual
outcome parameters. Therefore, we performed
Table 1. Injected Volumes per Experimental Group
Intervention groups
Volume
CABC (lL) BMP/vehicle (lL)
Healthy vehicle 130– 54 117– 37
TG-BMP-2
1 lg/mL
126– 29 151– 66
TG-BMP-2
5 lg/mL
116– 32 131– 32
TG-BMP-2/7
1 lg/mL
124– 37 120– 50
TG-BMP-2/7
5 lg/mL
150– 29 143– 51
Volumes of CABC and BMP or vehicle are represented as mean– SD.
BMP, bone morphogenetic protein; CABC, chondroitinase ABC; TG,
transglutaminase.
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additional analysis using linear mixed models with goat
as a random factor, which did not reveal any signiﬁcant
differences between the applied interventions either
(HYP content p = 0.07, T2* relaxation times p = 0.37,
histological grading p = 0.51).
Correlations
Figure 2 shows the scatter plots and correlations between
the MRI T2* relaxation times in the NP and the amount
of GAG, collagen content (HYP), and histological grad-
ing.We found a strong correlation between the T2* relax-
ation times and the amount of GAGs for theNP (q= 0.76,
p< 0.0001). Moderate, yet highly signiﬁcant, correlations
were observed between T2* relaxation times of the NP
and the collagen content (q=0.61, p< 0.0001) and his-
tological grading (q=0.53, p= 0.0002). Concerning the
inner and outer annulus ﬁbrosus, only weak and no sig-
niﬁcant correlations were found for T2* relaxation times
and other outcome parameters.
Discussion
In this study, we sought to establish the safety and ef-
ﬁcacy of a newly synthesized slow-release delivery sys-
tem for TG-BMP-2 and TG-BMP-2/7 for IVD repair
in a goat model of mild IVD degeneration. This
slow-release system, TG-BMP conjugated to a FB/HA
hydrogel carrier, appeared to be safe, as demonstrated
by the absence of any adverse effects like osteophytes,
heterotopic bone formation, or inﬂammation. Where
earlier in vivo studies showed the feasibility of restoring
degenerated IVDs by injecting BMP-2 or BMP-7 intra-
discally36,37 or delaying the degeneration process using
adenoviral vectors carrying the BMP-2 gene,7 this re-
generative effect was not observed in our goat IVDs.
We observed no statistically signiﬁcant differences be-
tween any of the treatment groups, while the individual
outcome parameters correlated well with each other.
The good correlations found indicate an accurate anal-
ysis of the different parameters and are in line with the
correlations found previously within our group.34
The absence of regenerative effects may have several
causes. First, the TG-BMP-2 and TG-BMP-2/7 dosages
may have simply been too low for a large animal. We
injected absolute amounts of maximal 1 lg TG-BMP-
2 or TG-BMP-2/7 in our goat model, based on previous
studies by our group, that is, a bone regeneration study
in rat cranial defects.29,30 Other in vivo studies, investi-
gating IVD regeneration, used 2-100-fold higher dos-
ages of BMP. Injection of 7.5 lg rhBMP-2 in a rat tail
disc degeneration model showed an improved MRI
disc grade, using a modiﬁed Pﬁrrmann grade, when
injected 4 weeks postannular puncture.36 BMP-7 was
evaluated in a rabbit degeneration model using either
2lg rhBMP-7 in 10lL saline37 or 100lg rhBMP-7
in 10lL lactose.19 In a very recent study, Willems
et al.38 injected an absolute dose of 2.5, 25 or 250 lg
rhBMP-7 per IVD in a canine model of spontaneous
IVD degeneration, also based on positive outcomes in
prior in vitro studies. However, like in our study, no re-
generative signs were observed. Their possible explana-
tion of the discrepancy between the in vitro and the
in vivo ﬁndings is the difference in addition frequency:
biweekly for in vitro use versus a single dose in vivo.
All these studies used a wild-type rhBMP, which is
not conjugated to a carrier and may therefore show a
faster release and concomitantly a shorter efﬁcacy
Table 2. Overview of Analyzed Parameters for Each
Experimental Intervention for the Nucleus Pulposus
and Statistical Analysis
T2* relaxation
time (msec)
GAG content
(lg/mg DW)
HYP content
(lg/mg DW)
Histological
grading
Control
Mean 58.31 366.51 26.44 1.75
SD 16.51 84.86 9.82 1.28
n 8 8 8 8
Vehicle
Mean 54.81 290.09 29.2 2.57
SD 17.27 69.48 8.67 1.4
n 6 7 7 7
TG-BMP-2
1 lg/mL
Mean 46.99 274.74 34.71 2.17
SD 13.96 77.18 8.09 0.75
n 6 6 6 6
TG-BMP-2
5 lg/mL
Mean 48.4 283.56 30.67 2.29
SD 13.35 52.28 10.71 1.5
n 7 7 7 7
TG-BMP-2/7
1 lg/mL
Mean 51.91 291.21 34.16 1.86
SD 16.31 62.53 10.97 1.57
n 7 7 7 7
TG-BMP-2/7
5 lg/mL
Mean 48.34 293.16 25.71 2.57
SD 10.51 66.54 3.24 1.27
n 7 7 7 7
Average
Mean 51.66 302.06 29.95 2.19
SD 14.49 72.93 9.13 1.29
n 41 42 42 42
ANOVA p= 0.67 p= 0.15 p= 0.32 p= 0.74
DW, dry weight; GAG, glycosaminoglycan; HYP, hydroxyproline; TG-
BMP-2/TG-BMP-2/7, the covalently bound growth factors BMP2 and
BMP-2/7 heterodimer to the ﬁbrin/hyaluronic acid hydrogel through a
transglutaminase moiety (TG).
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period, compared to the conjugated TG-BMP we used
for our study. This is substantiated by previous in vitro
experiments showing a 60% retention of the TG-BMP-
2 conjugated to ﬁbrin after 50 twelve-hour wash steps
with Tris-buffered saline, compared to 27% retention
for the wild-type rhBMP in ﬁbrin.29 Moreover, a four-
fold increase in cumulative release of rhBMP-2 was
found relative to both TG-BMP-2 and TG-BMP-2/7 di-
mers after a culture period of 2 weeks.30 We therefore
postulate that the longer sequestration of the BMPs by
the covalent conjugation to the hydrogel well compen-
sates for the lower amounts we used in comparison to
most other in vivo studies. Finally, the amounts used
in this study and the sequestration to the ﬁbrin hydrogel
were chosen to avoid reported risks of (extradiscal) oste-
ogenic induction, when applying high dosages of BMPs.
In a study by Huang et al., injection of 100lg rhBMP-2
in a rabbit annular tear degeneration model showed in-
ﬂammatory inﬁltrates, increased vascularity, osteophyte
formation, and endplate hypertrophy.39 These ﬁndings
point more toward spinal fusion, which we aimed to
avoid. Moreover, diffusion of nonsequestered rhBMP-
7 out of the IVD may cause adverse effects. This was
demonstrated in the before mentioned study of Willems
et al.,38 in which injection of the two highest dosages
rhBMP-7 resulted in extensive extradiscal bone forma-
tion. Thus, this further advocates the use of a sequestra-
tion/slow release system.
Besides the explanations mentioned earlier, our
follow-up time of 12 weeks could be too short for
any quantiﬁable, regenerative changes to occur. In
the studies mentioned previously, follow-up time var-
ied from 6 till 24 weeks post-BMP administration;
however, it is well known that repair mechanisms
may be faster in small animal models.40 The 12-week
follow-up for our study was chosen to be able to detect
a dose–response effect of the differently administered
concentrations, TG-BMP, before a plateau phase was
reached where results would be similar for all TG-
BMP treatment intervention groups.
Another hypothesis may be that the absence of a re-
generative effect is due to ineffective cleavage of the
TG-BMP from the hydrogel carrier because of a lack
of plasmin or molecules with the same function in
the IVD. The engineered TG-BMP fusion protein com-
prises a proteolytic, plasmin-sensitive cleavage domain
to allow slow release from the FB/HA hydrogel by local
enzymatic activity.29 Although plasmin is only found in
IVDs with a fractured endplate,41 suggesting blood-
borne instead of locally synthesized plasmin, there is
an upregulation of other extracellular matrix degrading
proteins like MMPs and ADAMTS in the mildly
degenerated IVD.35,42 Fibrin is one of the substrates
for MMPs and we hypothesized that the upregulation
of the MMPs would degrade the FB/HA hydrogel and
thereby release the TG-BMPs in the NP.43,44 Moreover,
the TG-BMP-2/7 heterodimer, conjugated to an FB/
HA hydrogel, showed an increase in glycosaminoglycan
synthesis of in vitro cultured bovine NP cells with an in-
creasing concentration of TG-BMP-2/7. No plasmin was
added to the culture medium, indicating activity of the
TG-BMP without active cleaving of the plasmin domain
(unpublished results FP7 Project ‘‘NPmimetic’’). Promp-
ted by the absence of regenerative effects, we aimed to
a b c
FIG. 2. Scatter plots and linear regression lines indicating correlations between MRI T2* relaxation times
(msec) and (a) glycosaminoglycan (GAG) content (lg/mg dry weight) (q = 0.76, p < 0.0001), (b) collagen (HYP)
content (lg/mg dry weight) (q =0.61, p < 0.0001), and (c) histological grade (range 0–6) (q =0.53,
p = 0.0002). q, Spearman’s rho correlation coefﬁcient; R2, linear regression coefﬁcient.
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assess whether the TG-BMPs were still retained in the
NP at the time of sacriﬁce. However, due to too low sen-
sitivity of assay methods for in vivo detection of the TG-
BMPs, we could not properly address this question.
To our knowledge, this is the ﬁrst study beyond
small animal models evaluating conjugated BMPs for
mild DD treatment; no large animal or clinical studies
have been reported so far. One major drawback of the
preceding in vivo studies, all performed in rodent and
rabbit models, is that these animals retain their noto-
chordal cells in adult life, whereas in humans and in
goats, the notochordal cells have disappeared at the
time of adolescence.45,46 The notochordal cells, also
regarded as NP precursor cells, are thought to play
a role in the maintenance of the extracellular matrix in
the NP and coordinate the function of the chondrocyte-
like NP cells.47 The presence of these cells could therefore
overestimate the effect of the regenerative therapies tested.
As notochordal cells are not present in the IVDs of a skel-
etally mature goat, we classify the goat as a more suitable
animal model to study regenerative therapies.
Future studies should compare the conjugated TG-
BMPs with the nonconjugated wild-type BMP-2 and
BMP-2/7 for regeneration of the IVD in a large animal
model, with longer follow-up times and including
higher dosages of TG-BMPs. Additional gene expres-
sion analysis by real time-PCR could be performed to
observe a possible shift from a catabolic to a more an-
abolic gene expression pattern.
Conclusion
To our knowledge, this is the ﬁrst large animal study
evaluating BMPs, conjugated to an FB-HA hydrogel,
for the regeneration of mildly degenerated IVDs. We
showed that a slow release BMP-2 and BMP-2/7 system
for IVD regeneration in goats, using engineered TG-
BMP-2 and TG-BMP-2/7 proteins, can be applied
safely in our goat model. However, no effect on disc re-
generation was observed, as demonstrated by the ab-
sence of statistically signiﬁcant differences between
any of the intervention groups. Possible explanations
are too low dosages of the TG-BMPs, the absence of
notochordal cells, short follow-up time, and/or insuf-
ﬁcient release of the conjugated TG-BMPs from the
injected hydrogel. Future studies should compare
the TG-conjugated BMPs with the nonconjugated
rhBMP-2 and BMP-2/7 for regeneration of the IVD
in a large animal model, with additional (longer)
follow-up times and including higher dosages of
TG-BMPs.
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AF ¼ annulus ﬁbrosis
ANOVA ¼ analysis of variance
BMP ¼ bone morphogenetic protein
CABC ¼ chondroitinase ABC
DHI ¼ disc height index
DW ¼ dry weight
FB ¼ ﬁbrin
GAG ¼ glycosaminoglycan
HA ¼ hyaluronic acid
HYP ¼ hydroxyproline
IVD ¼ intervertebral disc
MRI T2* ¼ MRI technique, a new method for the clinical assessment
of IVD degeneration
NP ¼ nucleus pulposus
pl ¼ plasmin
rhBMP ¼ recombinant human BMP
ROI ¼ region of interest
TG ¼ transglutaminase
TSE ¼ turbo spin echo
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